AC Immune (NASDAQ:ACIU – Get Free Report) and Kamada (NASDAQ:KMDA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Insider & Institutional Ownership
51.4% of AC Immune shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares AC Immune and Kamada”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AC Immune | $4.31 million | 52.42 | -$85.03 million | ($0.54) | -4.11 |
| Kamada | $180.46 million | 2.45 | $20.20 million | $0.38 | 20.26 |
Kamada has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
AC Immune has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Kamada has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for AC Immune and Kamada, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AC Immune | 1 | 1 | 3 | 0 | 2.40 |
| Kamada | 0 | 0 | 4 | 0 | 3.00 |
AC Immune currently has a consensus price target of $7.50, indicating a potential upside of 237.84%. Kamada has a consensus price target of $13.50, indicating a potential upside of 75.32%. Given AC Immune’s higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Kamada.
Profitability
This table compares AC Immune and Kamada’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AC Immune | -245.32% | -100.17% | -28.36% |
| Kamada | 11.60% | 8.37% | 5.85% |
Summary
Kamada beats AC Immune on 10 of the 14 factors compared between the two stocks.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
